WinstonWınston
Back
Adia Med logo

Adia Med

ADIA
Medical - Pharmaceuticals · Healthcare
Exchange
Other OTC
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Winston Score History

The full picture

Adia Med Inc. is a small pharmaceutical company focused on developing and commercializing medical treatments. The company operates in the healthcare sector, targeting patients and healthcare providers with its drug products or therapies. Like many small-cap pharma companies, it is in an early or growth stage of building out its commercial portfolio.

Adia Med generates revenue primarily through product sales, though its 27.4% gross margin and deeply negative operating margin suggest it is spending heavily on research, development, and operations relative to what it earns. The company appears to operate mainly in the United States, and with a market cap near zero, it is a very small player with limited financial resources compared to larger pharmaceutical firms. The central risk for Adia Med is its ability to fund ongoing operations and reach profitability, as its negative returns on capital indicate it is currently burning through more money than it brings in.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

EPS data limited

Insider Activity

8.2%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

$128,115 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Adia Med has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
58.2%
Premium pricing power — 58.2% gross margin
Profit after running costs
Operating Margin
10.7%
Modest — 10.7% operating margin
Return on the money invested
ROCE
11.4%
Below par — 11.4% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
N/A
Data not available
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
no trend
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial